Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer
ConditionLobular Breast Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIstituto Oncologico Veneto IRCCS
About this trial
The NAPOLI Study is a retrospective multicenter observational study designed to characterize negative hormone receptor and apocrine lobular invasive breast cancer. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.
Eligibility criteria
Qualifiers
Female or male patients aged ≥18 years.
Histologically confirmed invasive lobular carcinoma of the breast.
Presence of apocrine differentiation/features documented in pathology report or confirmed by local pathology review.
Negative hormone receptors.
Disqualifiers
Pure ductal carcinoma without lobular invasive component.
Metastatic tumor to the breast from non-breast primary cancer.
Insufficient pathological documentation to confirm eligibility.
Missing essential clinical data.
Trial design
Treatments tested in this trial
- Upfront Breast Surgery
- Adjuvant Radiotherapy
- Endocrine Therapy
- Chemotherapy
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov